Using a treat-to-target approach , open-label conventional synthetic disease-modifying antirheumatic drugs ( csDMARDs ) , other than MTX , were added from week 24 if Disease Activity Score in 28 joints based on erythrocyte sedimentation rate ( DAS28-ESR ) > 3.2 .